Source: Eur Respir J 2015; 46: 554-557



Rating:

Share or cite this content

Citations should be made in the following way:
Lhote Raphael, Theodore Christine, Issoufaly Tasnime, Francois Dominique, Kahn Jean-Emmanuel, Guillevin Loïc, Rivaud Elisabeth, Bron Camille, Vasse Marc, Couderc Louis-Jean, Tcherakian Colas. Successful treatment of antineutrophil cytoplasmic antibody-associated bronchiectasis with immunosuppressive therapy. Eur Respir J 2015; 46: 554-557

Member's Comments

No comment yet.

Related content which might interest you: Cure bronchiectasis associated with anti-neutrophil cytoplasmatic antibodies (ANCA) with immunosuppressive therapy Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 Prognosis of pulmonary fibrosis with usual interstitial pneumonia pattern in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-related nephritiss Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Antineutrophil cytoplasmic antibodies (ANCA) associated-bronchiectasis appears more severe than "idiopathic" bronchiectasis Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients Source: Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019 Year: 2020 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Antineutrophil cytoplasmic antibody (ANCA) associated lung-renal vasculitides: A single centre perspective Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 Pulmonary manifestations of myeloperoxidase-antineutrophil cytoplasmic antibody(MPO-ANCA)-related systemic vasculitis:CT findings in 50 patients Source: Eur Respir J 2002; 20: Suppl. 38, 267s Year: 2002 Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 ANCA (antineutrophil cytoplasmic autoantibody) in the chronic lower respiratory tract infection Source: Eur Respir J 2002; 20: Suppl. 38, 444s Year: 2002 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Cystic lesion in myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)- positive interstitial pneumonia: radiological and pathological anaylsis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Anti-endothelial cell antibodies in patients with idiopathic nonspecific interstitial pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 308s Year: 2006 Effect of anti-IL-17 biologics on KL-6 level and coexisting interstitial pneumoniain patients with psoriasis Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020 Challenges in the management of patients with ANCA- associated vasculitides Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012 Corticosteroid treatment in sarcoidosis Source: Eur Respir J 2006; 28: 627-636 Year: 2006 Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Lung involvement in ANCA associated crescentic glomerulonephritis Source: Eur Respir J 2005; 26: Suppl. 49, 31s Year: 2005